Search Results - "Dore, Gregory J."

Epidemiology and natural history of HCV infection by Hajarizadeh, Behzad, Grebely, Jason, Dore, Gregory J.

“…Globally, 130–170 million people have HCV infection; however, distribution patterns are highly variable. This Review outlines the latest information on the…”
Get full text

Direct-acting antiviral agents for HCV infection affecting people who inject drugs by Grebely, Jason, Hajarizadeh, Behzad, Dore, Gregory J.

“…Key Points HCV prevalence and incidence among people who inject drugs (PWID) remains high Direct-acting antiviral agents (DAA) for HCV with cure in >95%…”
Get full text

Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection by Phetsouphanh, Chansavath, Darley, David R., Wilson, Daniel B., Howe, Annett, Munier, C. Mee Ling, Patel, Sheila K., Juno, Jennifer A., Burrell, Louise M., Kent, Stephen J., Dore, Gregory J., Kelleher, Anthony D., Matthews, Gail V.

“…A proportion of patients surviving acute coronavirus disease 2019 (COVID-19) infection develop post-acute COVID syndrome (long COVID (LC)) lasting longer than…”
Get full text

Hepatitis C virus elimination: laying the foundation for achieving 2030 targets by Dore, Gregory J., Bajis, Sahar

“…The World Health Organization’s targets for hepatitis C elimination by 2030 are ambitious, but, in 2020, global leadership demonstrated by Egypt, innovative…”
Get full text

HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysis by Lockart, Ian, Yeo, Malcolm G. H., Hajarizadeh, Behzad, Dore, Gregory J., Danta, Mark, Abe, Kazumichi, Carrat, Fabrice, Lusivika‐Nzinga, Clovis, Degasperi, Elisabetta, Di Marco, Vito, Hou, Jinlin, Howell, Jessica, Janjua, Naveed Z, Wong, Stanley, Kumada, Takashi, Lleo, Ana, Persico, Marcello, Lok, Anna S, Wei, Lai, Yang, Ming, Nabatchikova, Ekaterina, Nguyen, Mindie H, Antonio Pineda, Juan, Reig, María, Shiha, Gamal, Yu, Ming‐Lung, Tsai, Pei‐Chien

“…Background and Aims HCV cure reduces but does not eliminate the risk of HCC. HCC surveillance is recommended in populations where the incidence exceeds 1.5%…”
Get full text

Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis by Hajarizadeh, Behzad, Cunningham, Evan B., Valerio, Heather, Martinello, Marianne, Law, Matthew, Janjua, Naveed Z., Midgard, Håvard, Dalgard, Olav, Dillon, John, Hickman, Matthew, Bruneau, Julie, Dore, Gregory J., Grebely, Jason

“…HCV reinfection following successful treatment can compromise treatment outcomes. This systematic review assessed the rate of HCV reinfection following…”
Get full text

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+) by Leroy, Vincent, Angus, Peter, Bronowicki, Jean‐Pierre, Dore, Gregory J., Hezode, Christophe, Pianko, Stephen, Pol, Stanislas, Stuart, Katherine, Tse, Edmund, McPhee, Fiona, Bhore, Rafia, Jimenez‐Exposito, Maria Jesus, Thompson, Alexander J.

“…Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced liver disease, are a challenging population in urgent need of…”
Get full text

The changing therapeutic landscape for hepatitis C by Dore, Gregory J

“…Summary The next decade will be a crucial period in the public health response to hepatitis C virus (HCV) infection. The rapid development of direct‐acting…”
Get full text

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial by Jacobson, Ira M, Prof, Dore, Gregory J, Prof, Foster, Graham R, Prof, Fried, Michael W, Prof, Radu, Monica, MD, Rafalsky, Vladimir V, Prof, Moroz, Larysa, Prof, Craxi, Antonio, Prof, Peeters, Monika, MSc, Lenz, Oliver, PhD, Ouwerkerk-Mahadevan, Sivi, PhD, De La Rosa, Guy, MD, Kalmeijer, Ronald, MD, Scott, Jane, PhD, Sinha, Rekha, PhD, Beumont-Mauviel, Maria, PhD

“…Summary Background Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon (peginterferon) alfa plus…”
Get full text

Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression by Thein, Hla‐Hla, Yi, Qilong, Dore, Gregory J., Krahn, Murray D.

“…Published estimates of liver fibrosis progression in individuals with chronic hepatitis C virus (HCV) infection are heterogeneous. We aimed to estimate…”
Get full text

Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis by Hajarizadeh, Behzad, Cunningham, Evan B, Reid, Hannah, Law, Matthew, Dore, Gregory J, Grebely, Jason

“…There are concerns around poorer response to direct-acting antiviral (DAA) therapy for hepatitis C virus infection among people who use drugs. This systematic…”
Get more information

Management of acute HCV infection in the era of direct-acting antiviral therapy by Martinello, Marianne, Hajarizadeh, Behzad, Grebely, Jason, Dore, Gregory J., Matthews, Gail V.

“…The management of acute HCV infection has not been standardized following the availability of direct-acting antiviral agents (DAAs) for chronic HCV infection,…”
Get full text

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation by Martin, Natasha K, Vickerman, Peter, Dore, Gregory J, Grebely, Jason, Miners, Alec, Cairns, John, Foster, Graham R, Hutchinson, Sharon J, Goldberg, David J, Martin, Thomas C.S, Ramsay, Mary, Hickman, Matthew

“…Graphical abstract…”
Get full text

Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications by Kwon, Jisoo A, Dore, Gregory J, Hajarizadeh, Behzad, Alavi, Maryam, Valerio, Heather, Grebely, Jason, Guy, Rebecca, Gray, Richard T

“…Australia was one of the first countries to introduce government-funded unrestricted access to direct-acting antiviral (DAA) therapy, with 88,790 treated since…”
Get full text

Mixed HCV infection and reinfection in people who inject drugs—impact on therapy by Cunningham, Evan B., Applegate, Tanya L., Lloyd, Andrew R., Dore, Gregory J., Grebely, Jason

“…Key Points As a result of ongoing high-risk behaviours, people who inject drugs (PWID) might commonly harbour mixed HCV infections and are at risk of…”
Get full text

Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy : a meta-analysis by THEIN, Hla-Hla, QILONG YI, DORE, Gregory J, KRAHN, Murray D

“…To estimate stage-specific transition probabilities in individuals coinfected with HIV and hepatitis C virus (HCV), to examine the effect of covariates on…”
Get full text

Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine by Grebely, Jason, Dr, Prins, Maria, Prof, Hellard, Margaret, Prof, Cox, Andrea L, Prof, Osburn, William O, PhD, Lauer, Georg, MD, Page, Kimberly, PhD, Lloyd, Andrew R, Prof, Dore, Gregory J, Prof

“…Summary Hepatitis C virus (HCV) was discovered more than two decades ago, but progress towards a vaccine has been slow. HCV infection will spontaneously clear…”
Get full text

Treatment adherence and support for people who inject drugs taking direct‐acting antiviral therapy for hepatitis C infection by Read, Phillip, Gilliver, Rosie, Kearley, John, Lothian, Rebecca, Cunningham, Evan B., Chronister, Karen J., Dore, Gregory J.

“…A community‐based public health facility in Sydney, Australia, the Kirketon Road Centre (KRC), provides health care to people who inject drugs (PWID), homeless…”
Get full text

Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries by Ghinea, Narcyz, BSc, Lipworth, Wendy, PhD, Day, Richard, Prof, Hill, Andrew, PhD, Dore, Gregory J, Prof, Danta, Mark, MD

“…HCV-related liver disease mortality is estimated to be half a million per annum.1,2 Chronic HCV treatment was interferon based for two decades, with the…”
Get full text

Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection by Bull, Rowena A, Luciani, Fabio, McElroy, Kerensa, Gaudieri, Silvana, Pham, Son T, Chopra, Abha, Cameron, Barbara, Maher, Lisa, Dore, Gregory J, White, Peter A, Lloyd, Andrew R

“…Hepatitis C is a pandemic human RNA virus, which commonly causes chronic infection and liver disease. The characterization of viral populations that…”
Get full text